Target intelligence / Profile preview

Coli surface antigen 3 (CS3)

Target
CS3
Molecular classification
Bacterial adhesin, Fimbrial protein, Other
01

Overview

Coli surface antigen 3 (CS3) is a major fimbrial adhesin (specifically a thin, flexible, wiry fibrilla) expressed on the surface of enterotoxigenic Escherichia coli (ETEC). It is a key component of the colonization factor antigen II (CFA/II) complex and plays a critical role in mediating bacterial adherence to host intestinal epithelial cells, which is the initial and essential step for ETEC colonization and subsequent diarrheal disease. CS3 is composed of the major structural subunit CstH (also known as CS3 fimbrial subunit A) and is assembled via a chaperone-usher pathway. Due to its high prevalence in clinical ETEC isolates associated with moderate-to-severe diarrhea in children in developing countries and in travelers, CS3 is a primary target for vaccine development. Several vaccine candidates, including the oral inactivated vaccine ETVAX and the live attenuated vaccine ACE527, incorporate CS3 to elicit protective mucosal IgA and systemic IgG antibody responses that block bacterial colonization. Additionally, CS3 has been identified as a host receptor for specific bacteriophages (such as IMM-002), highlighting its potential as a target for phage therapy.

Other names
CS3 fimbrial antigenCS3 pilinCS3 fimbrial subunit ACstHCFA/II component 3
02

Mechanism of action

Active immunization to elicit mucosal IgA and systemic IgG antibodies that bind to CS3, thereby blocking bacterial attachment to host intestinal epithelial cells and preventing colonization. Additionally, it serves as a receptor for specific bacteriophages (e.g., IMM-002) to mediate phage infection and lysis of enterotoxigenic Escherichia coli (ETEC).

03

Biological functions

Bacterial adhesionImmune responseOther
04

Disease associations

InfectionOther
05

Safety considerations

Potential for poor immunogenicity when administered orally without an adjuvant (e.g., dmLT)Antigenic variation and heterogeneity among ETEC strains, requiring multivalent formulations for broad protectionRisk of mild gastrointestinal side effects (e.g., diarrhea, abdominal pain) when using live attenuated vaccine strains
06

Interacting drugs

5 more in the full profile.

07

Biomarkers

Anti-CS3 IgA antibody titerAnti-CS3 IgG antibody titerCS3-specific antibody-secreting cells (ASCs)Antibody in lymphocyte supernatant (ALS) IgA

Beyond the preview

Go deeper on Coli surface antigen 3 (CS3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Coli surface antigen 3 (CS3).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call